🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK — grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≤24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months — use filters for patent-cliff planning.

Page 10 of 18

  1. US 10745471

    Method of treating osteoarthritis with an antibody to NGF

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10738124

    Anti-EGFRvIII antibodies and uses thereof

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10736976

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10736961

    Method of averting opioid addiction

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10737113

    Human antibodies to PD-1

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10738130

    Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10738126

    Anti-GITR antibodies and uses thereof

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10730948

    Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10730944

    Anti-CD8 antibodies and uses thereof

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10711032

    Steroids and protein-conjugates thereof

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10689436

    Human antibodies to influenza hemagglutinin

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10683354

    Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10676530

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10662244

    Methods for tumor treatment using CD3XCD20 bispecific antibody

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10640566

    Nucleic acid molecules encoding antibodies to the human glucagon receptor

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10640558

    Anti-IL-25 antibodies and uses thereof

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10633434

    Anti-C5 antibodies

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10632194

    Anti-ErbB3 antibodies and uses thereof

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10626173

    Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR

    Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10618968

    Antigen-binding proteins that activate the leptin receptor

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10588940

    Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10584173

    Nucleic acids encoding high affinity antibodies to human IL-6 receptor

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10582702

    Non-human animals having an engineered ANGPTL8 gene

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10570151

    Biologically active molecules, conjugates thereof, and therapeutic uses

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10561126

    Genetically modified non-human animals and methods of use thereof

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10562953

    GPR156 variants and uses thereof

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10550192

    Antigen-binding proteins that antagonize leptin receptor

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10550193

    Methods and antibody compositions for tumor treatment

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10548302

    Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10544232

    Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10532096

    Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody

    Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10524458

    Humanized C3 animals

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10526344

    Amino acid acylation reagents and methods of using the same

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10526403

    Anti-activin A antibodies and uses thereof

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10525106

    Angiopoietin-based interventions for treating cerebral malaria

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10525104

    Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10519240

    Anti-FGFR1c antibody-FGF21 fusion proteins

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10519230

    Nucleic acids encoding IL-33 antibodies

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10513557

    Anti-ASIC1 antibodies and uses thereof

    Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10501526

    Human antibodies to Ebola virus glycoprotein

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10492477

    Humanized C5 animals

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10494442

    Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10485844

    Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10472425

    Stabilized formulations containing anti-PCSK9 antibodies

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10463749

    Maytansinoid derivatives, conjugates thereof, and methods of use

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10463028

    Genetically modified non-human animals expressing human EPO

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10463029

    Rodent model of steel syndrome

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10464992

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.